Welcome to our dedicated page for Entera Bio SEC filings (Ticker: ENTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial read-outs, equity offerings, and shifting FDA timelines make Entera Bio Ltd’s disclosures dense. Investors hunting for cash runway details or the latest osteoporosis data often get lost in 100-page forms that blend Israeli corporate law with U.S. GAAP notes. Our filings hub turns that complexity into clarity—think of it as "Entera Bio SEC filings explained simply."
Stock Titan’s AI instantly flags "Entera Bio insider trading Form 4 transactions" and pushes "Entera Bio Form 4 insider transactions real-time" alerts to your dashboard. Scroll further to see each "Entera Bio quarterly earnings report 10-Q filing" linked to concise ratios, while the "Entera Bio annual report 10-K simplified" section translates risk factors and R&D spend into plain English. Need context on financing rounds? The "Entera Bio 8-K material events explained" card pairs every capital raise with dilution analytics. For governance questions, check "Entera Bio proxy statement executive compensation" and follow "Entera Bio executive stock transactions Form 4" alongside peer benchmarks. It’s "understanding Entera Bio SEC documents with AI" in action, delivering "Entera Bio earnings report filing analysis" minutes after EDGAR posts.
Because Entera’s pipeline hinges on costly Phase 2/3 trials, monitoring burn rate, partnership milestones, and at-the-market offerings matters. Our platform surfaces these metrics, highlights orphan-drug strategy disclosures, and tracks patent updates in real time. Spend less time parsing PDFs and more time judging whether Entera’s oral peptide platform can redefine osteoporosis care.
Entera Bio Ltd. reported consolidated cash, cash equivalents and restricted cash of $18.9 million as of June 30, 2025, up from $9.1 million a year earlier, driven by equity financings and a collaboration payment held in escrow. The company recorded a six‑month net loss of $5.2 million (loss per share $0.12), increasing R&D spend to $2.6 million as it prepares for an EB613 Phase 3 program and advances the OPKO collaboration on oral OXM.
Management states available funds should support operations through the middle of the third quarter of 2026 under current plans but excludes the capital required to initiate the EB613 Phase 3 study, and the filing notes this raises substantial doubt about the company’s ability to continue as a going concern. Material near‑term developments include a $8.0 million issuance to OPKO (3,685,226 shares) placed in escrow to fund collaborative program costs and the FDA’s written concurrence (July 28, 2025) that a single 24‑month multinational Phase 3 with total hip BMD primary endpoint can support an NDA for EB613.
Entera Bio Ltd. furnished a Current Report on Form 8-K stating that on August 8, 2025 the company issued a press release announcing its financial results and business updates for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02 and Item 7.01 of the report. The filing clarifies that the information is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act and therefore is not automatically subject to the liabilities of that section or to incorporation by reference in other filings unless explicitly done so.
FAQ
What is the current stock price of Entera Bio (ENTX)?
What is the market cap of Entera Bio (ENTX)?
